Glassy Mountain Advisors’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$7.45M Sell
47,531
-3,094
-6% -$464K 2.04% 18
2026
Q1
$7.73M Buy
50,625
+188
+0.4% +$28.8K 2.4% 18
2025
Q4
$6.95M Sell
50,437
-63
-0.1% -$8.25K 2.1% 18
2025
Q3
$6.48M Sell
50,500
-937
-2% -$114K 1.95% 20
2025
Q2
$6.22M Buy
51,437
+1,071
+2% +$121K 2% 19
2025
Q1
$5.61M Sell
50,366
-193
-0.4% -$20.5K 1.99% 21
2024
Q4
$4.92M Buy
50,559
+1,776
+4% +$189K 1.68% 23
2024
Q3
$5.61M Buy
48,783
+1,374
+3% +$156K 1.97% 21
2024
Q2
$5.05M Buy
47,409
+1,717
+4% +$172K 1.87% 21
2024
Q1
$4.42M Buy
45,692
+2,449
+6% +$251K 1.66% 25
2023
Q4
$4.37M Buy
43,243
+703
+2% +$67.9K 1.8% 23
2023
Q3
$4.32M Sell
42,540
-792
-2% -$80.4K 2.06% 22
2023
Q2
$4.37M Buy
+43,332
New +$4.33M 1.95% 19
2023
Q1
Sell
-39,380
Closed -$3.57M 162
2022
Q4
$3.57M Buy
+39,380
New +$3.32M 1.97% 19
2022
Q2
$3.06M Sell
36,180
-1
-0% -$88 1.83% 21
2022
Q1
$3.17M Buy
36,181
+1,163
+3% +$101K 1.63% 23
2021
Q4
$3.06M Buy
+35,018
New +$2.91M 1.58% 24

Other funds holding NVS

Glassy Mountain Advisors's NVS Position: Q2 2026 in Review

Glassy Mountain Advisors reduced its Novartis (NVS) stake by 6.1% in Q2 2026, selling an estimated $464K and leaving 47,531 shares worth $7.45M. The position accounts for 2.04% of the portfolio, ranked #18.

Glassy Mountain Advisors first reported a position in NVS in Q4 2021 and has held it in 17 quarters since. The position peaked at $7.73M in Q1 2026. 1,620 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Glassy Mountain Advisors held 47,531 shares of Novartis worth $7.45M as of Q2 2026.
  • Glassy Mountain Advisors sold 3,094 Novartis shares in Q2 2026, an estimated $464K.
  • Novartis made up 2.04% of Glassy Mountain Advisors's portfolio in Q2 2026, its #18 holding.
  • Glassy Mountain Advisors first reported a position in Novartis in Q4 2021 and has held it in 17 quarters since.
  • Glassy Mountain Advisors's Novartis position peaked at $7.73M in Q1 2026.
  • 1,620 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Glassy Mountain Advisors's 13F filing for Q2 2026, filed 31 Jul 2026.